Mumbai, Maharashtra, India Joined 01 September 2010
Soranib Tablets
Soranib Tablets

Soranib Tablets

Buyer Feedback
Posted by : Mr Bhavesh Shah
Offered by : PHAMAZON OVERSEAS PVT. LTD.
Last updated on : Aug 21,2015
Product added on : Sep 06,2014
Product Code : AC-SB
Send Inquiry Have a question?   Ask Supplier
Product Description
SORANIB IS EQUIVALENT AS NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate is a white to yellowish or brownish solid with a molecular formula of C21H16ClF3N4O3 x C7H8O3S and a molecular weight of 637.0 g/mole. Sorafenib tosylate is practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400. Each red, round NEXAVAR film-coated tablet contains sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib and the following inactive ingredients: croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium lauryl sulphate, magnesium stearate, polyethylene glycol, titanium dioxide and ferric oxide red.
About the Supplier

Established in 2017, Phamazon Overseas Pvt. Ltd. has been a leading name in offering top notch Health Care Products. Located in Mumbai, Maharashtra, we offer the best quality Soranib Tablets to our customers at best prices in the industry.

  • Nature of Business
    Exporter / Manufacturer / Supplier
  • Number of Employees
    18
  • Year of Establishment
    2017
  • Annual Turnover
    Rs 2 Crores
  • Working Days
    Monday - Saturday
Send your inquiry directly to this supplierReceiver's Company Name: Phamazon Overseas Pvt. Ltd.

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.

Send this inquiry to other Suppliers of similar products (?)
I agree to abide by all the Terms and Conditions of tradeindia.com
Contact Details
Phamazon Overseas Pvt. Ltd.
1/a Empress Business Bay, Near Uti Mutual Fund, Road No 11, Midc, Andheri East,
Mumbai, Maharashtra, 400093, India
Contact Supplier
Mr Bhavesh ShahDirector
Last updated on : 27 October 2018 Report Incorrect Contact
You May Also Be Interested In